Comparing two conditioning regimens for stem cell transplant in AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial compares two drug combinations used before a stem cell transplant to see which is safer and more effective for people with acute myeloid leukemia (AML) that is in remission but still has minimal residual disease (MRD). The goal is to help prevent the leukemia from coming back after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 16 and 65 years old.
- You have acute myeloid leukemia (AML) that is in remission (fewer than 5% blasts in bone marrow) but still has minimal residual disease (MRD).
- You have a suitable stem cell donor (matched sibling, unrelated donor, or half-matched family donor).
- Your major organs (heart, liver, kidneys, lungs) are functioning well enough, as confirmed by tests.
- You are willing to sign informed consent and follow the treatment plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of total body irradiation and two chemotherapy drugs (busulfan and melphalan) given before a stem cell transplant. It is for people with acute myeloid leukemia that has come back or not responded to standard treatment.
This trial tests a combination of two drugs (SHR2554 and azacitidine) given before a stem cell transplant for people with high-risk or relapsed leukemia or MDS. The goal is to see if this approach can help make the transplant more effective and reduce the chance of the disease coming back.
This study tests a less intense chemotherapy conditioning regimen before a stem cell transplant in people with myelodysplastic syndromes (MDS), a type of blood cancer where the bone marrow doesn't make enough healthy blood cells. The aim is to see if this approach is safer and still works well, potentially helping more people qualify for transplant.
This trial tests a special combination of chemotherapy drugs (called a conditioning regimen) given before a half-matched stem cell transplant for older adults with acute myeloid leukemia (AML) in their first remission. The goal is to make the transplant safer and more effective for people aged 55 to 75.
This trial is testing two different chemotherapy regimens (with one or two alkylating agents) before a stem cell transplant for people with acute myeloid leukemia or myelodysplastic syndrome. The goal is to find which conditioning treatment is safer and more effective.
This trial tests a stronger chemotherapy regimen before a stem cell transplant to see if it can reduce the chance of leukemia coming back. It is for adults with acute myeloid leukemia who are in first remission.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.